Acrotech has a responsibility to step up to the plate and confirm the clinical benefits of its suboptimally developed accelerated approval drugs, FDA's Richard Pazdur said. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
